Results 11 to 20 of about 445,623 (380)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
John J. Ryan, Lana Melendres-Groves, Roham T. Zamanian, Ronald J. Oudiz, Murali Chakinala, Erika B. Rosenzweig, Mardi Gomberg-Maitland   +6 more
doaj   +2 more sources

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension

ERJ Open Research, 2023
Background Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH).
Anna M. Dittrich, Julia Mienert, Julian Pott, Lena Engels, Christoph Sinning, Jan K. Hennigs, Hans Klose, Lars Harbaum   +7 more
doaj   +1 more source

Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential

Frontiers in Cardiovascular Medicine, 2023
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance and pulmonary artery pressure. Mortality remains high in severe cases despite significant advances in management and pharmacotherapy.
Jakob Körbelin, Julius Klein, Julius Klein, Christiane Matuszcak, Christiane Matuszcak, Johannes Runge, Johannes Runge, Lars Harbaum, Hans Klose, Jan K. Hennigs, Jan K. Hennigs   +10 more
doaj   +1 more source

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension

ERJ Open Research, 2023
Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH).
Jonna Ostermann, Julian Pott, Jan K. Hennigs, Kevin Roedl, Christoph Sinning, Lars Harbaum, Hans Klose   +6 more
doaj   +1 more source

Sotatercept for the Treatment of Pulmonary Arterial Hypertension.

New England Journal of Medicine, 2021
BACKGROUND Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, R. Souza, A. Waxman, P. Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. Barnes, P. Linde, J. de Oliveira Pena, D. Badesch   +17 more
semanticscholar   +1 more source

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

European Respiratory Journal, 2022
Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, Rogério Souza, A. Waxman, H. Ghofrani, P. Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. de Oliveira Pena, D. Badesch   +16 more
semanticscholar   +1 more source

A cluster of heritable pulmonary arterial hypertension cases in a family with all three siblings carrying the same novel AQP1 c.273C>G variant‐a case report

Pulmonary Circulation, 2023
Approximately 25%–30% of patients diagnosed with idiopathic pulmonary arterial hypertension (PAH) have a clustered underlying Mendelian genetic cause and should be classified as heritable PAH (HPAH).
Kae‐Woei Liang, Sheng‐Kai Chang, Yu‐Wei Chen, Wan‐Jane Tsai, Kuo‐Yang Wang   +4 more
doaj   +1 more source

Endothelial cells in the pathogenesis of pulmonary arterial hypertension

European Respiratory Journal, 2021
Pulmonary arterial hypertension (PAH) is a devastating disease that involves pulmonary vasoconstriction, small vessel obliteration, large vessel thickening and obstruction, and development of plexiform lesions.
C. Evans, N. Cober, Z. Dai, D. Stewart, You-yang Zhao   +4 more
semanticscholar   +1 more source

Molecular Pathways in Pulmonary Arterial Hypertension

International Journal of Molecular Sciences, 2022
Pulmonary arterial hypertension is a multifactorial, chronic disease process that leads to pulmonary arterial endothelial dysfunction and smooth muscular hypertrophy, resulting in impaired pliability and hemodynamics of the pulmonary vascular system, and
Aangi J Shah, Mounica Vorla, D. Kalra
semanticscholar   +1 more source

The physiological basis of pulmonary arterial hypertension

European Respiratory Journal, 2021
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) failure.
R. Naeije, M. Richter, L. Rubin
semanticscholar   +1 more source